Report cover image

Liver Health Supplements Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Publisher Global Market Insights
Published Dec 09, 2024
Length 111 Pages
SKU # GMI19463487

Description

Liver Health Supplements Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032


Global Liver Health Supplements Market will exhibit a 5.6% CAGR between 2024 and 2032 due to advancements in supplement formulations and growing consumer preference for natural products. Innovations in combining effective herbal ingredients with modern delivery systems enhance the efficacy and appeal of these supplements. Consumers increasingly seek natural, plant-based solutions for liver health, reflecting a shift towards holistic and preventive approaches. This trend towards incorporating advanced formulations and natural ingredients aligns with the demand for safe, effective, and sustainable liver health solutions, thus fueling industry growth.

For instance, in March 2023, Gencor introduced 4Liver, an Ayurvedic liver health supplement combining Terminalia chebula fruit and Sphaeranthus indicus flower extracts, both traditionally used for liver support in Ayurvedic medicine. This development indicates a rising consumer interest in holistic and herbal approaches to liver health, expanding the market to include more diverse and culturally rooted products. It also reflects a broader acceptance of Ayurvedic solutions and the integration of time-tested herbal ingredients into modern health supplements.

The liver health supplements industry is segmented based on product, use, dosage form, distribution channel, and region.

The tablets segment will witness a remarkable market share by 2032, fueled by their convenience, precise dosage, and widespread consumer preference. Tablets offer a practical and consistent way for individuals to incorporate liver health supplements into their daily routines. They are easy to store, transport, and administer, making them a popular choice among consumers. Besides, the ability to include a wide range of active ingredients in tablet form enhances their appeal, contributing to their dominance in the industry.

The vitamins segment will gain a considerable foothold by 2032, owing to their essential role in supporting liver function and overall health. Vitamins such as B-complex, C, and E are well-regarded for their liver-protective properties, including detoxification and antioxidant support. Consumers increasingly seek these beneficial nutrients to maintain liver health and prevent liver-related issues. The widespread recognition of vitamins' health benefits and their integration into daily health routines contribute to their leading position in the liver health supplements market.

Asia Pacific liver health supplements industry share will expand at a noteworthy CAGR through 2032, attributed to rising health awareness, increasing urbanization, and growing disposable incomes across the region. As lifestyle-related liver issues become more prevalent, consumers are seeking supplements to support liver function and overall health. Additionally, traditional practices and natural remedies in many Asian cultures contribute to the demand for liver health supplements. The region’s growing industry, influenced by both contemporary and traditional health practices, establishes it as a primary contributor to global market expansion.

Table of Contents

111 Pages
Chapter 1 Methodology
1.1 Market segmentation
1.2 Market definitions
1.3 Research design
1.4 Market size estimates and calculations
1.4.1 Approach 1: Company share analysis
1.4.2 Approach 2: Patient population
1.5 Key trends for market estimates
1.6 Forecast model
1.7 Primary research & validation
1.7.1 Primary sources
1.7.2 Data mining sources
1.7.2.1 Paid sources
1.7.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry landscape, 2021 - 2032 (USD Bn)
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Type trends
2.1.4 Drug class trends
2.1.5 Route of administration trends
2.1.6 Medication type trends
2.1.7 Gender trends
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising burden of liver cancer
3.2.1.2 Increasing R&D investments for the development of novel therapies
3.2.1.3 Rising aging population
3.2.1.4 Government initiatives to increase cancer awareness
3.2.2.1 Side effects associated with certain medications
3.2.2.2 High cost of cancer therapies
3.3 Growth potential analysis
3.3.1 By type
3.3.2 By drug class
3.3.3 By route of administration
3.3.4 By medication type
3.3.5 By gender
3.4 Pipeline analysis
3.5 Regulatory landscape
3.5.1 U.S.
3.5.2 Europe
3.6 Future market trends
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.1.1 Bayer AG
4.1.2 AstraZeneca plc
4.1.3 F. Hoffmann-La Roche Ltd.
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Liver Cancer Drugs Market, By Type
5.1 Hepatocellular carcinoma
5.2 Cholangiocarcinoma
5.3 Hepatoblastoma
5.4 Liver metastasis
5.5 Other liver cancer types
Chapter 6 Liver Cancer Drugs Market, By Drug Class
6.1 Targeted therapy drugs
6.2 Chemotherapeutic agents
6.3 Immunotherapy drugs
Chapter 7 Liver Cancer Drugs Market, By Route of Administration
7.1 Injectable
7.2 Oral
Chapter 8 Liver Cancer Drugs Market, By Medication Type
8.1 Branded
8.2 Generic
Chapter 9 Liver Cancer Drugs Market, By Gender
9.1 Male
9.2 Female
Chapter 10 Liver Cancer Drugs Market, By Region
10.1 North America
10.2 Europe
10.3 Asia Pacific
10.4 Latin America
10.5 Middle East and Africa
Chapter 11 Company Profiles
11.1 Amgen Inc.
11.1.1 Global overview
11.1.2 Business overview
11.1.3 Financial data
11.1.3.1 Annual sales revenue, 2020-2023 (USD Million)
11.1.4 Product landscape
11.1.4.1 SWOT analysis
11.2 AstraZeneca plc
11.2.1 Global overview
11.2.2 Business overview
11.2.3 Financial data
11.2.3.1 Annual sales revenue, 2020-2023 (USD Million)
11.2.4 Product landscape
11.2.5 Strategic outlook
11.2.6 SWOT analysis
11.3 Bayer AG
11.3.1 Global overview
11.3.2 Business overview
11.3.3 Financial data
11.3.3.1 Annual sales revenue, 2020-2023 (USD Million)
11.3.4 Product Landscape
11.3.5 SWOT analysis
11.4 Bristol-Myers Squibb Company
11.4.1 Global overview
11.4.2 Business overview
11.4.3 Financial data
11.4.3.1 Annual sales revenue, 2020-2023 (USD Million)
11.4.4 Product Landscape
11.4.5 Strategic outlook
11.4.6 SWOT analysis
11.5 Eisai Co., Ltd.
11.5.1 Global overview
11.5.2 Business overview
11.5.3 Financial data
11.5.3.1 Annual sales revenue, 2020 - 2023 (USD Million)
11.5.4 Product landscape
11.5.5 SWOT analysis
11.6 Eli Lilly and Company
11.6.1 Global overview
11.6.2 Business overview
11.6.3 Financial data
11.6.3.1 Annual sales revenue, 2020 - 2023 (USD Million)
11.6.4 Product landscape
11.6.5 SWOT analysis
11.7 Exelixis, Inc
11.7.1 Global overview
11.7.2 Business overview
11.7.3 Financial data
11.7.3.1 Annual sales revenue, 2020 - 2023 (USD Million)
11.7.4 Product landscape
11.7.5 SWOT analysis
11.8 F. Hoffmann-La Roche Ltd.
11.8.1 Global overview
11.8.2 Business overview
11.8.3 Financial data
11.8.3.1 Annual sales revenue, 2020 - 2023 (USD Million)
11.8.4 Product landscape
11.8.5 SWOT analysis
11.9 Incyte
11.9.1 Global overview
11.9.2 Business overview
11.9.3 Financial data
11.9.3.1 Annual sales revenue, 2020-2023 (USD Million)
11.9.4 Product landscape
11.9.5 SWOT analysis
11.10 Merck & Co. Inc.
11.10.1 Global overview
11.10.2 Business overview
11.10.3 Financial data
11.10.3.1 Annual sales revenue, 2020-2023 (USD Million)
11.10.4 Product Landscape
11.10.5 SWOT analysis
11.11 Pfizer Inc.
11.11.1 Global overview
11.11.2 Business overview
11.11.3 Financial data
11.11.3.1 Annual sales revenue, 2020-2023 (USD Million)
11.11.4 Product Landscape
11.11.5 SWOT analysis
11.12 Sanofi
11.12.1 Global overview
11.12.2 Business overview
11.12.3 Financial data
11.12.3.1 Annual sales revenue, 2020-2023 (USD Million)
11.12.4 Product landscape
11.12.5 SWOT analysis
11.13 Taiho Pharmaceutical Co., Ltd.
11.13.1 Global overview
11.13.2 Business overview
11.13.3 Financial data
11.13.3.1 Annual sales revenue, 2020-2023 (USD Million)
11.13.4 Product Landscape
11.13.5 SWOT analysis ©Global Market Insights Inc. All Rights Reserved. Page | 10 Liver Cancer Drugs Market Report, 2032 Data Tables TABLE 1. Liver cancer drugs market, 2021 - 2024 (USD Million) 24 TABLE 2. Liver cancer drugs market, 2025 - 2032 (USD Million) 24 TABLE 3. Liver cancer drugs market, by region, 2021 - 2024 (USD Million) 25 TABLE 4. Liver cancer drugs market, by region, 2025 - 2032 (USD Million) 26 TABLE 5. Liver cancer drugs market, by type, 2021 - 2024 (USD Million) 27 TABLE 6. Liver cancer drugs market, by type, 2025 - 2032 (USD Million) 27 TABLE 7. Liver cancer drugs market, by drug class, 2021 - 2024 (USD Million) 28 TABLE 8. Liver cancer drugs market, by drug class, 2025 - 2032 (USD Million) 28 TABLE 9. Liver cancer drugs market, by route of administration, 2021 - 2024 (USD Million) 30 TABLE 10. Liver cancer drugs market, by route of administration, 2025 - 2032 (USD Million) 30 TABLE 11. Liver cancer drugs market, by medication type, 2021 - 2024 (USD Million) 31 TABLE 12. Liver cancer drugs market, by medication type, 2025 - 2032 (USD Million) 31 TABLE 13. Liver cancer drugs market, by gender, 2021 - 2024 (USD Million) 32 TABLE 14. Liver cancer drugs market, by gender, 2025 - 2032 (USD Million) 32 TABLE 15. Liver cancer incidence and rate, by country, 2022 37 TABLE 16. Pipeline analysis 50 TABLE 17. Competitive benchmarking of major market players 62 TABLE 18. Competitive positioning matrix: Classification criteria 63 ©Global Market Insights Inc. All Rights Reserved. Page | 11 Liver Cancer Drugs Market Report, 2032 Charts & Figures FIG. 1 Research design 16 FIG. 2 Company share analysis 18 FIG. 3 Patient population 19 FIG. 4 Forecast approach & model 20 FIG. 5 Breakdown of respondents 21 FIG. 6 Global liver cancer drugs market, 2021 - 2032 (USD Bn) 24 FIG. 7 Industry ecosystem analysis 33 FIG. 8 Percent of cases by stage at diagnosis: liver and intrahepatic bile duct cancer, 2014-2020 38 FIG. 9 Distribution of liver cancer incidence in Victoria, by age group, in 2022 41 FIG. 10 Growth potential analysis, by type 45 FIG. 11 Growth potential analysis, by drug class 46 FIG. 12 Growth potential analysis, by route of administration 47 FIG. 13 Growth potential analysis, by medication type 48 FIG. 14 Growth potential analysis, by gender 49 FIG. 15 Porter's analysis 55 FIG. 16 PESTEL analysis 56 FIG. 17 Company matrix analysis 59 FIG. 18 Company market share analysis, 2023 60 FIG. 19 Competitive analysis of major market players 61 FIG. 20 Competitive positioning matrix 62 FIG. 21 Strategy dashboard 64 FIG. 22 Number of people aged 60 years or over in Asia and the Pacific, by subregion, 2022, 2030, and 2050 (in Million) 81 ©Global Market Insights Inc. All Rights Reserved. Page | 12 Liver Cancer Drugs Market Report, 2032

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us